Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The small-cap player in the U.S. generics market had strong revenue and growth over the past few years, which "was driven in large part by strategic price increaseas, and the acquisition of Kremers Urban Pharmaceuticals," Gilbert noted.
Lannett has a good sized generic drug pipeline to foster more growth, but in the United States, the tailwind from price growth has slowed and competitive pressures have intensified.
Lannett has a higher product concentration than its peers. Levothyroxine and Ursodiol "account for approximately one-third of sales and a higher portion of profits," Gilbert stated. While Levothyroxine has a pretty strong hold on its market, Ursodiol could face greater competition from generics at any time. The lack of geographic diversity also negatively impacts Lannett's drug portfolio.
In Gilbert's view, rising competition in the generics market will muffle any positive growth Lannett is able to muster.
At time of writing, Lannett was down 0.80 percent on the day at $23.56.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.